Achieve Life Sciences, Inc.
ACHV
$5.99
$0.407.16%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 121.84% | 92.96% | 76.49% | 82.12% | 115.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.84% | 17.86% | 49.01% | 115.55% | 177.93% |
| Operating Income | -20.84% | -17.86% | -49.01% | -115.55% | -177.93% |
| Income Before Tax | -18.62% | -15.42% | -50.31% | -97.52% | -125.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.62% | -15.42% | -50.31% | -97.52% | -125.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.62% | -15.42% | -50.31% | -97.52% | -125.71% |
| EBIT | -20.84% | -17.86% | -49.01% | -115.55% | -177.93% |
| EBITDA | -20.95% | -17.96% | -49.37% | -116.57% | -180.25% |
| EPS Basic | 23.15% | 22.27% | -48.76% | -42.61% | -38.42% |
| Normalized Basic EPS | 20.86% | 20.65% | -48.53% | -42.81% | -47.64% |
| EPS Diluted | 23.15% | 22.27% | -48.76% | -42.61% | -38.42% |
| Normalized Diluted EPS | 20.86% | 20.65% | -48.53% | -42.81% | -47.64% |
| Average Basic Shares Outstanding | 54.38% | 48.50% | 1.07% | 38.47% | 63.05% |
| Average Diluted Shares Outstanding | 54.38% | 48.50% | 1.07% | 38.47% | 63.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |